Clinovo Announces Expansion of CRO Network
Clinovo, a provider of cloud-based e-clinical software, has unveiled plans to expand its CRO partner scheme involving ClinCapture, its electronic data capture (EDC) system. Ten new CRO partners have been added in the U.S., Russia, Spain, Mexico, India, and Japan.
The company’s program claims to offer an array of benefits, including free training for certified partners, exclusivity on lead generation, extensive marketing and sales support, as well as special partner discounts.
ClinCapture is a free, validated EDC system incorporating role-based, intuitive software. With the recent product updates, CROs can spend time building their clinical database and manage electronic case report forms (CRFs), according to the vendor. Partner companies can also access an extensive CDASH CRF Library built by Clinovo.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
